Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Small Cell Lung Carcinoma 576Breast Neoplasms 419Neoplasms 299Adenocarcinoma of Lung 248Colorectal Neoplasms 222Melanoma 201Mesothelioma, Malignant 183Pancreatic Neoplasms 179Prostatic Neoplasms 178Brain Neoplasms 178Head and Neck Neoplasms 172Neoplasm Metastasis 167Ovarian Neoplasms 153Esophageal Neoplasms 152Mesothelioma 145Colonic Neoplasms 140Stomach Neoplasms 139NSCLC 115Pleural Effusion, Malignant 114Carcinoma, Renal Cell 109Urinary Bladder Neoplasms 105Disease 96Sarcoma 85Uterine Cervical Neoplasms 82Thymoma 79Liver Neoplasms 77Motor Activity 75Squamous Cell Carcinoma of Head and Neck 72

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor × Thoracic × Clear all
NCT04216121 2024-07-01

LAT-FLOSI

Universitaire Ziekenhuizen KU Leuven

Recruiting
39 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Kunming Medical University

Phase NA Recruiting
30 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡